Trusted Resources: News & Events
Latest announcements and gatherings
Hydroxyurea Treatment in Men with SCA Leads to Drop in Total Sperm Count, Study Shows
Researchers found that treatment with hydroxyurea at currently approved doses for sickle cell anemia leads to a significant drop in total sperm count in men.
The study, “Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after six months of treatment,” was published in the journal Blood.
Progress in the treatment of sickle cell anemia (SCA) has allowed patients to live longer lives, reach reproductive age, and have children. One of the main reasons for the improvement in mortality and morbidity in patients with SCA is treatment with hydroxyurea.
+myBinderRelated Content
-
Bone Marrow Transplantation: A Treatment Option for Sickle Cell DiseaseBone marrow transplantation is the only ...
-
The role of nutrition in the pathophysiology and management of sickle cell disease among children: A review of liter...Sickle cell disease (SCD) is one of the ...
-
Greenville program tries team approach to improve lifespan of sickle cell disease patientsDr. Alan Anderson who was involved with ...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
University Hospitals program uses music to teach about sickle cell (photos, video)The study looked at Seidman's BEATS (Bui...
-
What it’s like to be 17 and living with sickle cell diseaseTre Adegoroye is 17 and was diagnosed wi...
-
A Conversation on Hydroxyurea: Insights and Information for the Sickle Cell Communityhttps://www.youtube.com/watch?v=Y6fmJn-5...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.